(RTTNews) - Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company, reported a loss in the third quarter loss and also provided updates on its pipeline programs advancing treatments for chronic inflammatory and liver diseases.
The company's lead drug candidate Aramchol Meglumine, is a first-in-class, liver-targeted stearoyl-CoA desaturase 1 (SCD1) modulator being developed as an oral therapy for nonalcoholic steatohepatitis (NASH) and fibrosis.
In a Phase 2b study, Aramchol demonstrated dose-dependent improvements in NASH resolution and fibrosis with an excellent safety profile. Based on these findings, Aramchol 300mg BID was selected for the ongoing ARMOR Phase 3 trial in patients with NASH and advanced fibrosis.
In addition to Aramchol, Galmed is advancing Amilo-5MER, a novel five-amino-acid peptide targeting the fibrillation of Serum Amyloid A (SAA) to disrupt chronic inflammatory pathways. Amilo-5MER is currently in a Phase 1 first-in-human trial assessing safety, tolerability, and pharmacokinetics in healthy volunteers, with potential applications in ulcerative colitis and other chronic inflammatory diseases.
The company is also collaborating on MyBiotics, a microbiome-based program aimed at modulating gut flora for potential application in NASH and fibrosis.
For the third quarter ended September 30, 2025, Galmed reported a net loss of $1.89 million, or $0.33 per share, compared with a net loss of $1.91 million, or $2.31 per share, in Q3 2024.
Research and development expenses rose to $1.1 million from $0.7 million a year earlier, while general and administrative expenses decreased to $1.0 million from $1.3 million.
Financial income, net, improved to $0.2 million from $0.1 million in the prior-year quarter.
GLMD has traded in the range of $0.74 to $3.61 over the past year. The stock is currently trading in the pre-market at $0.88, down 3.71%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
